Phaim Phaim

Diabetes Mellitus

Type 1 diabetes mellitus (T1DM) is a chronic, life-altering form of diabetes mellitus that results from autoimmune destruction of insulin-producing beta cells of the pancreas, resulting in a reduction and eventually in complete cessation of endogenous (one's own) insulin production. It can be induced by a combination of factors, including genetics, environment, and exposure to certain immune triggers. The cause is not yet fully understood, but significant recent advances have been made and DMX4001 our novel Antigenic Immune Modulation (AIM) therapy represents a potentially significant advance in the management and treatment of the condition.

T1DM has to date been treated by insulin therapy, where the amount of insulin administered is estimated against expected needs to control blood sugar levels. This is expensive, cumbersome and results in poor outcomes for the patients. Recently, western markets have seen an increased use of pump therapy in T1DM particularly in the US, whereas other developed markets are lagging, and multiple daily insulin injections are still the mode of treatment. Nevertheless none is able to provide continuous normal blood sugar, the ultimate goal in diabetes patients. A treatment that enables a reduction in or elimination of the need for insulin therapy in the management of the condition would be highly attractive both from patient and health economic perspectives.

Various attempts at developing immunotherapeutic management of T1DM have been attempted in the past, including:

  • Immunosuppressive drugs
  • Steroid therapy
  • Stem Cells

Many of these approaches have been unsuccessful. However, the Company now proposes a new approach to treating this condition that is expected to revolutionise the lives of millions of T1DM patients in the future. DMNoMore founder, Dr Tihamer Orban, is a world-leader in the field of the immunological mechanisms underlying T1DM.

Pharmaceutical companies are fully aware of the potential of an immunological approach to preventing diabetes and realise the major unmet need. Pharmaceutical companies have invested and committed to invest over $1bn to date on licencing deals for product development and clinical studies. Most of the ongoing studies use monoclonal antibodies that non-selectively suppress T cells to target the small and elusive subset of T cells attacking beta cells in the pancreas. These drugs are not specific to diabetes, and suppress large segments of the immune system, and long-term use may cause serious side effects. Our AIM therapeutic drug DMZ4001 is potentially a ground-breaking innovation based on in-depth knowledge of the T1DM disease process, utilising immunomodulation rather than immunosuppression.

The Technology

It is the Board's intention that the AIM therapy will be designed to function by boosting the natural balance of the immune system to re-establish immune health. The AIM therapy will address the underlying immunological challenge thereby arresting the self-destruction of pancreatic insulin producing cells and preserving insulin self-production.

Therapeutic Market - T1DM